Anti-Vascular Endothelial Growth Factor Biosimilars for Use in the Aging Eye

Area of Science:

• Ophthalmology
• Pharmacology
• Biotechnology

Background:

• Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss.
• Anti-vascular endothelial growth factor (anti-VEGF) therapies are standard treatments for nAMD and other retinal vascular diseases.
• High costs of anti-VEGF biologics necessitate alternative treatment options.

Purpose of the Study:

• To review the current landscape of anti-VEGF biosimilars for retinal diseases.
• To evaluate the clinical efficacy, safety, and economic implications of these biosimilars.
• To address challenges and future directions for biosimilar integration in ophthalmic practice.

Main Methods:

• Literature review of anti-VEGF biosimilars in development and approval.
• Analysis of clinical trial data on efficacy and safety.
• Examination of regulatory, physician, and patient acceptance factors.

Main Results:

• Several anti-VEGF biosimilars (e.g., bevacizumab, ranibizumab, aflibercept) are in development/approval.
• Biosimilars demonstrate comparable visual acuity improvements and retinal fluid reduction in nAMD.
• Challenges include regulatory hurdles, acceptance, and need for post-marketing surveillance.

Conclusions:

• Anti-VEGF biosimilars present a promising, cost-effective option for managing nAMD and other retinal vascular diseases.
• Successful integration requires addressing regulatory, acceptance, and safety monitoring challenges.
• Continued data generation and approvals are expected to increase biosimilar use in ophthalmology.